TrialEuropean journal of heart failure2020

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.

Patrick Rossignol et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.